Skip to main
ATOS
ATOS logo

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc. is positioned favorably due to its focus on developing novel therapeutics addressing significant unmet medical needs, particularly in oncology and COVID-19. The company’s lead drug, Endoxifen, along with its COVID-19 treatments AT-H201 and AT-301, have potential to create substantial value, supported by attractive current valuations that suggest upside from the current share price. Additionally, anticipated key clinical milestones and data may serve as critical catalysts for enhancing investor confidence and driving stock performance.

Bears say

Atossa Therapeutics Inc reported a net loss of $8.4 million, translating to an earnings per share (EPS) of $(0.07), which was below both internal and consensus estimates of $(0.06). The company faces multiple significant risks including liquidity challenges, potential failures in clinical trials for its drug candidates, and hurdles in obtaining regulatory approvals and reimbursement for its products. Furthermore, increased competition and shifting investor sentiment toward biotech stocks may compound the already challenging landscape for Atossa, heightening the overall uncertainty surrounding its financial outlook.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Nov 6, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.